SCHEMBL1993511

SCHEMBL1993511

CCN1CCC(Cn2nc(C3=C(c4c[nH]c5sccc45)C(=O)NC3=O)c3ccccc32)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 4/20 0.45
PRKCB P05771 11/20 0.42
PRKCA P17252 11/20 0.42
PRKCG P05129 10/20 0.42
PRKCD Q05655 6/20 0.42
PRKCE Q02156 4/20 0.42
CAMK2B Q13554 3/20 0.42
CAMK2G Q13555 3/20 0.42
CAMK2A Q9UQM7 3/20 0.42
SRC P12931 2/20 0.42
PRKCH P24723 2/20 0.42
PRKCZ Q05513 2/20 0.42
GSK3B P49841 13/20 0.40
KCNH2 Q12809 2/20 0.40
PRKACA P17612 2/20 0.39
PRKACG P22612 2/20 0.39
PRKACB P22694 2/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
PDGFRB P09619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1992218 0.92 CAMK2D (0.49) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1995677 0.91 CAMK2D (0.49) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1990609 0.90 CAMK2D (0.44) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1997092 0.90 CAMK2D (0.44) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1999866 0.90 CAMK2D (0.44) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1997361 0.89 CAMK2D (0.45) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1990076 0.88 CAMK2D (0.48) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1997364 0.88 CAMK2D (0.47) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1991812 0.88 CAMK2D (0.45) CAMK2DPRKCBPRKCAPRKCGPRKCD
SCHEMBL1992095 0.87 CAMK2D (0.43) CAMK2DPRKCBPRKCAPRKCGPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO CAMK2D 2963/4885PRKCB 3335/4885PRKCA 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.